Arena Pharmaceuticals Q4 Loss Widens - Quick Facts

Arena Pharmaceuticals Inc. (ARNA) reported fourth-quarter net loss allocable to common stockholders of $23.5 million, or $0.11 per share, wider than $21.3 million, or $0.10 per share in the comparable quarter last year. On average, 12 analysts polled by Thomson Reuters expected earnings of $0.02 for the quarter. Analysts' estimates typically exclude one-time items.

Revenues for the latest fourth-quarter were $6.52 million, up from $1.94 million in the year-ago period, twelve analysts estimated revenues of $35.54 million for the quarter.

Arena expects 2014 revenues of approximately $9.0 million from amortization of upfront payments from existing collaborations, approximately $7.0 million in development and patent reimbursements from Eisai, and approximately $1.0 million from manufacturing services for Siegfried.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT